Bone Biologics Statistics
Total Valuation
Bone Biologics has a market cap or net worth of $1.43 million. The enterprise value is -$1.35 million.
Market Cap | 1.43M |
Enterprise Value | -1.35M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
Earnings Date | May 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Bone Biologics has 879,175 shares outstanding. The number of shares has increased by 452.14% in one year.
Shares Outstanding | 879,175 |
Shares Change (YoY) | +452.14% |
Shares Change (QoQ) | -32.84% |
Owned by Insiders (%) | 8.15% |
Owned by Institutions (%) | 1.26% |
Float | 480,932 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.58 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.50, with zero debt.
Current Ratio | 4.50 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -236.00% and return on invested capital (ROIC) is -324.40%.
Return on Equity (ROE) | -236.00% |
Return on Assets (ROA) | -154.80% |
Return on Capital (ROIC) | -324.40% |
Revenue Per Employee | n/a |
Profits Per Employee | -$4.47M |
Employee Count | 2 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.17% in the last 52 weeks. The beta is 0.58, so Bone Biologics's price volatility has been lower than the market average.
Beta (1Y) | 0.58 |
52-Week Price Change | -97.17% |
50-Day Moving Average | 2.47 |
200-Day Moving Average | 4.92 |
Relative Strength Index (RSI) | 38.78 |
Average Volume (30 Days) | 87,680 |
Short Selling Information
The latest short interest is 15,106, so 1.72% of the outstanding shares have been sold short.
Short Interest | 15,106 |
Short Previous Month | 31,089 |
Short % of Shares Out | 1.72% |
Short % of Float | 3.14% |
Short Ratio (days to cover) | 0.10 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -9.43M |
Pretax Income | -8.95M |
Net Income | -8.95M |
EBITDA | -8.95M |
EBIT | -8.95M |
Earnings Per Share (EPS) | -$34.01 |
Balance Sheet
The company has $3.03 million in cash and no debt, giving a net cash position of $3.03 million or $3.44 per share.
Cash & Cash Equivalents | 3.03M |
Total Debt | n/a |
Net Cash | 3.03M |
Net Cash Per Share | $3.44 |
Equity / Book Value | 2.91M |
Book Value Per Share | 3.31 |
Working Capital | 2.91M |
Cash Flow
Operating Cash Flow | -9.56M |
Capital Expenditures | n/a |
Free Cash Flow | -9.56M |
FCF Per Share | -$36.32 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Bone Biologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -452.14% |
Shareholder Yield | -452.14% |
Earnings Yield | -534.11% |
FCF Yield | -570.35% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 20, 2023. It was a reverse split with a ratio of 1:8.
Last Split Date | Dec 20, 2023 |
Split Type | Reverse |
Split Ratio | 1:8 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |